title: A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases.
abstract: Affinity proteins have advanced the field of targeted therapeutics due to their generally higher specificity compared to small molecular compounds. However, side effects caused by on-target binding in healthy tissues are still an issue. Here, we design and investigate a prodrug strategy for improving tissue specificity of Affibody molecules in future in vivo studies. The prodrug Affibody (pro-Affibody) against the HER2 receptor was constructed by fusing a HER2-specific Affibody (ZHER2) to an anti-idiotypic Affibody (anti-ZHER2). The linker was engineered to comprise a substrate peptide for the cancer-associated matrix metalloprotease 1 (MMP-1). The hypothesis was that the binding surface of ZHER2 would thereby be blocked from interacting with HER2 until the substrate peptide was specifically hydrolyzed by MMP-1. Binding should thereby only occur where MMP-1 is overexpressed, potentially decreasing on-target toxicities in normal tissues. The pro-Affibody was engineered to find a suitable linker and substrate peptide, and the different constructs were evaluated with a new bacterial display assay. HER2-binding of the pro-Affibody was efficiently masked and proteolytic activation of the best variant yielded over 1,000-fold increase in apparent binding affinity. Biosensor analysis revealed that blocking of the pro-Affibody primarily affected the association phase. In a cell-binding assay, the activated pro-Affibody targeted native HER2 on cancer cells as opposed to the non-activated pro-Affibody. We believe this prodrug approach with proteolytic activation is promising for improving tissue specificity in future in vivo targeting applications and can hopefully be extended to other Affibody molecules and similar affinity proteins as well.
authors.affiliation: Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, 106 91, Stockholm, Sweden.
authors.forename: Lisa
authors.initials: L
authors.lastname: Sandersjöö
authors.forename: Andreas
authors.initials: A
authors.lastname: Jonsson
authors.forename: John
authors.initials: J
authors.lastname: Löfblom
mesh_terms: D001667:Binding, Competitive / Q000276:immunology; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000378:metabolism*; D011355:Prodrugs / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding / Q000276:immunology; D059748:Proteolysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D020349:Surface Plasmon Resonance
chemical_list: D020781:Matrix Metalloproteinase 1; D010447:Peptide Hydrolases; D011355:Prodrugs; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; C533351:affibody (ZHER2-342)2